Cindunistat HCl maleate
| Code | Size | Price |
|---|
| TAR-T30939-5mg | 5mg | £850.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Cindunistat( PHA-728669F, PF-00572986, PHA-84250, SD-6010, and SC-084250) is a potent and oral selective iNOS inhibitor which is expected to be used in patients with symptomatic osteoarthritis of the knee.
CAS:
753491-31-5
Formula:
C20H39ClN6O8S2
Molecular Weight:
591.14
Purity:
0.98
SMILES:
Cl.OC(=O)C=C/C(O)=O.CC(N)=NCCSC[C@](C)(N)C(O)=O.CC(N)=NCCSC[C@](C)(N)C(O)=O
References
1. Hellio le Graverand MP, Clemmer RS, Redifer P, Brunell RM, Hayes CW, Brandt KD, Abramson SB, Manning PT, Miller CG, Vignon E. A 2-year randomised, double-blind, placebo-controlled, multicentre study of oral selective iNOS inhibitor, cindunistat (SD-6010), in patients with symptomatic osteoarthritis of the knee. Ann Rheum Dis. 2013 Feb;72(2):187-95. doi: 10.1136/annrheumdis-2012-202239. Epub 2012 Nov 10. PubMed PMID: 23144445.